Literature DB >> 20160527

Cirrhotics admitted to intensive care unit: the impact of acute renal failure on mortality.

Evangelos Cholongitas1, Marco Senzolo, David Patch, Steve Shaw, James O'Beirne, Andrew K Burroughs.   

Abstract

BACKGROUND: The exact role of renal dysfunction in critically ill cirrhotics admitted to an intensive care unit (ICU) has not been assessed extensively. AIM: To evaluate the impact of acute renal failure (ARF) on 6 weeks mortality in cirrhotics admitted to ICU. PATIENTS/
METHODS: Three hundred and twelve cirrhotics (182 male, mean age 49.6+/-11.5 years) were consecutively admitted during the study period. The patients (n=128, 40%) (group 1) with ARF on admission and/or during ICU were compared with the patients whose ICU stay was not complicated with ARF (n=184, 60%) (group 2). At admission, 40 variables were available, whereas Child-Turcotte-Pugh, Model for End-stage Liver Disease, Acute Physiology and Chronic Health Evaluation II, Sequential Organ Failure Assessment and Failure Organ System scores on admission, were evaluated and compared by receiver operating characteristic curves.
RESULTS: Group 1, compared with group 2 patients, had longer ICU stay (7 vs. 4 days, P=0.04) and required cardiovascular support more frequently with inotropes (90 vs. 75%), (P<0.001). Mortality was significantly higher in group 1, compared with group 2 (91 vs. 47%, P<0.001). At admission, group 1, compared with group 2, had significantly higher Child-Turcotte-Pugh (12 vs. 11), Acute Physiology and Chronic Health Evaluation II (22 vs. 17), Model for End-stage Liver Disease (31 vs. 21), Sequential Organ Failure Assessment (13 vs. 9) and Failure Organ System (3 vs. 2) scores (P<0.001). In group 1, factors independently associated with mortality were: higher FiO2 (P=0.044), bilirubin (P=0.021) and creatinine (P=0.002) on admission. Mortality was not significantly different between those with ARF on admission, and those who developed ARF during ICU stay.
CONCLUSION: ARF at admission or during ICU stay is strongly predictive of mortality, which is high, despite supportive therapeutic interventions. Preventive measures are needed to prevent ARF, to improve prognosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20160527     DOI: 10.1097/MEG.0b013e328308bb9c

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  32 in total

Review 1.  [Hepatorenal syndrome in decompensated cirrhosis : A special form of acute renal failure].

Authors:  K Lenz; R Buder; G Lohr; P Piringer; M Voglmayr
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-05-30       Impact factor: 0.840

2.  Serum lactate level predict mortality in elderly patients with cirrhosis.

Authors:  Adnan Tas; Erdem Akbal; Yavuz Beyazit; Erdem Kocak
Journal:  Wien Klin Wochenschr       Date:  2012-07-19       Impact factor: 1.704

Review 3.  Role of cardiovascular intervention as a bridge to liver transplantation.

Authors:  Zankhana Raval; Matthew E Harinstein; James D Flaherty
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

4.  Prognosis of Patients with Cirrhosis and AKI Who Initiate RRT.

Authors:  Andrew S Allegretti; Xavier Vela Parada; Nwamaka D Eneanya; Hannah Gilligan; Dihua Xu; Sophia Zhao; Jules L Dienstag; Raymond T Chung; Ravi I Thadhani
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-09       Impact factor: 8.237

Review 5.  [Extracorporeal therapies in hepatic diseases].

Authors:  D Jarczak; G Braun; V Fuhrmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-05-08       Impact factor: 0.840

6.  Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis.

Authors:  Ayse L Mindikoglu; Antone R Opekun; Nagireddy Putluri; Sridevi Devaraj; David Sheikh-Hamad; John M Vierling; John A Goss; Abbas Rana; Gagan K Sood; Prasun K Jalal; Lesley A Inker; Robert P Mohney; Hocine Tighiouart; Robert H Christenson; Thomas C Dowling; Matthew R Weir; Stephen L Seliger; William R Hutson; Charles D Howell; Jean-Pierre Raufman; Laurence S Magder; Cristian Coarfa
Journal:  Transl Res       Date:  2017-12-12       Impact factor: 7.012

Review 7.  [Extracorporeal therapy of patients with liver disease in the intensive care unit].

Authors:  V Fuhrmann; T Horvatits; A Drolz; K Rutter
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-27       Impact factor: 0.840

8.  Urine albumin-to-creatinine ratio is associated with the severity of liver disease, renal function and survival in patients with decompensated cirrhosis.

Authors:  Evangelos Cholongitas; Ioannis Goulis; Maria Ioannidou; Stergios Soulaidopoulos; Parthenis Chalevas; Evangelos Akriviadis
Journal:  Hepatol Int       Date:  2016-08-30       Impact factor: 6.047

9.  Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus.

Authors:  Juan P Arab; Juan C Claro; Juan P Arancibia; Jorge Contreras; Fernando Gómez; Cristian Muñoz; Leyla Nazal; Eric Roessler; Rodrigo Wolff; Marco Arrese; Carlos Benítez
Journal:  World J Hepatol       Date:  2016-09-08

10.  Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis.

Authors:  Andrew S Allegretti; Guillermo Ortiz; Jie Cui; Julia Wenger; Ishir Bhan; Raymond T Chung; Ravi I Thadhani; Zubin Irani
Journal:  Am J Kidney Dis       Date:  2016-03-16       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.